Priscille Brodin

Title: Priscille Brodin: Innovator in Tuberculosis Treatment

Introduction

Priscille Brodin is a notable inventor based in Lille, France. She has made significant contributions to the field of medicine, particularly in the treatment of tuberculosis. Her innovative approach focuses on utilizing materials made of cross-linked β-cyclodextrins to enhance drug delivery and efficacy against multi-drug resistant tuberculosis.

Latest Patents

Priscille Brodin holds a patent for the "Use of materials made of cross-linked β-cyclodextrins for the treatment of tuberculosis." This patent addresses a critical public health issue, as multi-drug resistant tuberculosis affects approximately half a million individuals annually. Current treatment regimens are cumbersome, requiring patients to adhere to a strict regimen of over 10,000 tablets over a two-year period. Brodin's research highlights the potential of nanoparticles made from cross-linked poly-β-cyclodextrins as efficient drug carriers for pulmonary delivery of anti-TB drugs. These nanoparticles not only serve as drug carriers but also possess intrinsic antibacterial properties, impairing the establishment of Mycobacterium tuberculosis (Mtb) in the lungs.

Career Highlights

Throughout her career, Priscille Brodin has worked with esteemed institutions such as the National Institute of Health and Medical Research and the Centre National de la Recherche Scientifique. Her work has been pivotal in advancing the understanding of how cross-linked β-cyclodextrins can be utilized in drug formulations to combat tuberculosis effectively.

Collaborations

Priscille has collaborated with notable colleagues, including Ruxandra Gref and Arnaud Machelart. Their combined expertise has contributed to the development of innovative solutions for tuberculosis treatment.

Conclusion

Priscille Brodin's work exemplifies the intersection of innovation and public health. Her patent on cross-linked β-cyclodextrins represents a promising advancement in the fight against tuberculosis, showcasing her commitment to improving patient outcomes.